Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Oct
08
Today In Oncology
Charles Perou 2026 William L. McGuire Memorial Lecture Award
Starting Surveillance Colonoscopy After High-Risk Adenoma Removal When Is the Right Time
Robotic Esophagectomy Improves Lymph Node Yield in Esophageal Cancer
ACS Report Highlights Cancer Burden and Screening Disparities in U.S. Hispanic Population
Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo